These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30212391)

  • 1. FIGO Versus Silverberg Grading Systems in Ovarian Endometrioid Carcinoma: A Comparative Prognostic Analysis.
    Parra-Herran C; Bassiouny D; Vicus D; Olkhov-Mitsel E; Cesari M; Ismiil N; Nofech-Mozes S
    Am J Surg Pathol; 2019 Feb; 43(2):161-167. PubMed ID: 30212391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological grading of ovarian mucinous carcinoma - an outcome-based analysis of traditional and novel systems.
    Busca A; Nofech-Mozes S; Olkhov-Mitsel E; Gien LT; Bassiouny D; Mirkovic J; Djordjevic B; Parra-Herran C
    Histopathology; 2020 Jul; 77(1):26-34. PubMed ID: 31782197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading ovarian serous carcinoma using a two-tier system.
    Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
    Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis.
    Lax SF; Kurman RJ; Pizer ES; Wu L; Ronnett BM
    Am J Surg Pathol; 2000 Sep; 24(9):1201-8. PubMed ID: 10976693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome-based Validation of Confluent/Expansile Versus Infiltrative Pattern Assessment and Growth-based Grading in Ovarian Mucinous Carcinoma.
    Momeni-Boroujeni A; Song H; Irshaid L; Strickland S; Parra-Herran C; Busca A
    Am J Surg Pathol; 2022 Sep; 46(9):1250-1259. PubMed ID: 35363158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 9. Architectural versus nuclear atypia-defined FIGO grade 2 endometrial endometrioid adenocarcinoma (EEC): a clinicopathologic comparison of 154 cases with clinical follow-up.
    Winham WM; Lin D; Stone PJ; Nucci MR; Quick CM
    Int J Gynecol Pathol; 2014 Mar; 33(2):120-6. PubMed ID: 24487465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
    El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
    Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group.
    Yamamoto S; Kasajima A; Takano M; Yaegashi N; Fujiwara H; Kuzuya K; Kigawa J; Tsuda H; Kurachi H; Kikuchi Y; Sugiyama T; Tsuda H; Moriya T
    Int J Gynecol Pathol; 2011 Mar; 30(2):129-38. PubMed ID: 21293288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma.
    Ayhan A; Taskiran C; Yuce K; Kucukali T
    Int J Gynecol Pathol; 2003 Jan; 22(1):71-4. PubMed ID: 12496701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems.
    Alkushi A; Abdul-Rahman ZH; Lim P; Schulzer M; Coldman A; Kalloger SE; Miller D; Gilks CB
    Am J Surg Pathol; 2005 Mar; 29(3):295-304. PubMed ID: 15725797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters.
    Kapucuoglu N; Bulbul D; Tulunay G; Temel MA
    Int J Gynecol Cancer; 2008; 18(4):790-6. PubMed ID: 17892460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
    Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
    Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system.
    Shimizu Y; Kamoi S; Amada S; Hasumi K; Akiyama F; Silverberg SG
    Gynecol Oncol; 1998 Jul; 70(1):2-12. PubMed ID: 9698465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of tumor grade on survival end points and patterns of recurrence of 949 patients with early-stage endometrioid carcinoma: a single institution study.
    Gayar OH; Patel S; Schultz D; Mahan M; Rasool N; Elshaikh MA
    Int J Gynecol Cancer; 2014 Jan; 24(1):97-101. PubMed ID: 24264358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
    Kuwabara Y; Susumu N; Banno K; Hirao T; Kawaguchi M; Yamagami W; Suzuki N; Aoki D; Nozawa S
    Jpn J Clin Oncol; 2005 Jan; 35(1):23-7. PubMed ID: 15681600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
    Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.